메뉴 바로가기 본문 바로가기
Products AlphaLiquid®
The AlphaLiquid® Series
AlphaLiquid®
10
AlphaLiquid®
100
AlphaLiquid®
1000
AlphaLiquid®
Screening
AlphaLiquid®
MRD
Companion diagnostics
Recurrence & metastasis
monitoring
Biomarker discovery
Early diagnosis
Personalized residual
disease monitoring
  • AlphaLiquid®
    10
  • AlphaLiquid®
    100
  • AlphaLiquid®
    1000

Treatment selection

Recurrence monitoring

AlphaLiquid®
Screening

Early detection

AlphaLiquid®
MRD

Personalized residual
disease monitoring

AlphaLiquid®10(Colon)
  • AlphaLiquid®10 is designed to detect mutations in 10 colorectal cancer-related genes.
  • It can be used in companion diagnostics to provide information on whether recurrence or metastasis might be occurring after treatment.
  • Target cancer

    Colorectal cancer

  • Detectable mutations

    SNV, Indel

AlphaLiquid®100
  • AlphaLiquid®100 tests for variations in 106 guideline-recommended, cancer-related genes.
  • It provides information about which anticancer drug associated with each gene, any clinical trial being conducted, and the type of mutations (SNV, Indel, CNV, fusion, as well as MSI) that occurred.
  • It can be used in companion diagnostics to detect and monitor signs of relapse and/or metastasis after beginning anticancer drug therapy.
  • Target cancers

    Colorectal, lung, breast, ovarian, pancreatic, stomach, liver, skin cancer

  • Detectable mutations

    SNV, Indel, CNV, fusion, MSI(microsatellite instability)

AlphaLiquid®1000
  • AlphaLiquid®1000 is a pan-cancer assay for almost all known types of solid cancer patients, designed to examine more than a 1000 genes related to different cancers at once.
  • It, too, can be used in companion diagnostics to detect and monitor signs of relapse and/or metastasis after beginning anticancer drug therapy.
  • Target cancers

    Colorectal, lung, breast, ovarian, stomach, pancreatic, prostate, brain, skin, thyroid, and most other cancers

  • Detectable mutations

    SNV, Indel, fusion, CNV, MSI + TMB(tumor mutational burden)

AlphaLiquid®Screening
  • AlphaLiquid®Screening is able to detect cancer faster than imaging tests such as CT or MRI scan.
  • It is designed to screen and detect cancer early by identifying where the cancer first originated in the body.
  • This allows the doctor to begin treatment at an earlier stage which increases the patient’s chances of survival.
  • Designed for

    Cancer patients & healthy people

  • Detectable variation

    Changes in DNA methylation pattern

AlphaLiquid®MRD
  • AlphaLiquid®MRD is designed as a personalized tracking & monitoring test for cancer patients.
  • It evaluates each individual patient’s mutational profile to search for residual tumor remaining in the patient after therapy, allowing fast and accurate detection of a possible relapse of cancer.
  • Target cancers

    Colorectal, lung, breast, ovarian, stomach, pancreatic, prostate, brain, skin, thyroid, and most other cancers

  • Detectable biomarker

    Minimal Residual Disease(MRD)

AlphaLiquid Tube™
  • AlphaLiquid Tube™ is a tube developed for convenient collection and storage of blood, as well as for effective cfDNA extraction. Collected blood can be stored in room temperature for up to 10 days.
  • AlphaLiquid Tube™ is made of break-resistant material, so there is lower risk of damage and/or leakage of sample during shipment.